Analysis of acylcarnitine profiles in children with idiopathic epilepsy using valproic acid

Amaç: Valproik asit (VPA) tedavisi alan epilepsili çocuklarda plazma açil-karnitin düzeylerinin etkilenip etkilenmeyeceğini araştırmak amaçlı yapılmıştır. Materyals ve Metods: En az bir yıldır VPA tedavisi alan 50 epilepsili çocuk (ortalama yaş, 10±3.9) ve benzer yaştaki 110 çocuk control grubu olarak incelenmiştir. Serbest karnitin ve açilkarnitin düzeyleri Tandem Mass Spectrometry (Tandem-MS) yöntemi kullanılarak ölçülmüştür. Sonuçlar: Serbest karnitin düzeyleri normal olarak saptanmıştır. Valproik asitin aşağıda belirtilen açilkarnitin düzeylerini kontrol grubu ile karşılaştırıldığında istatistiksel olarak anlamlı bir şekilde etkilediği (p

Valproik asit kullanan idiyopatik epilepsili çocuklarda açil karnitin profillerinin değerlendirilmesi

Purpose: To evaluate whether valproic acid (VPA) treatment in children with epilepsy affects the plasma fatty acylcarnitine esters. Materials and Methods: Fifty children (mean age, 10±3.9) with epilepsy receiving VPA treatment for at least one year were evaluated along with 110 children of similar age as a control group. Levels of free carnitine and acylcarnitine profiles were studied with tandem mass spectrometry (Tan-dem-MS). Results: Free camitine levels were within the normal limits. Valproic acid was found to affect the levels of the following individual acylcarnitines (medians): C4-acylcarnitine (0.56 umol/L; controls 0.39 umol/L), 3-hyd-roxy-isovalerylcamitine (C5-OH) (0.23 umol/L; controls 0.14 umol/L), C14-acylcarnitine (0.11 umol/L; controls 0.16 umol/L), C16-acylcarnitine (0.76 umol/L; controls 2.5 umol/L), C16-OH-acylcarnitine (0.04 umol/L; controls 0.07umol/L), and Cl8:1-acylcarnitine (0.8 umol/L; controls 0.97 umol/L). A statistical comparison of these acylcarnitines between subjects and controls showed a statistically significant effect (p

PDF

___

1.Chung S, Choi J, Hyun T. Alterations in the carnitine metabolism in epileptic children treated with valproic acid. J Korean Med Sci 1997;12:553-558.
2.Segade SR, Pena CA, Tutor JC. Carnitine deficiency associated with anticonvulsant therapy. ClinChimActa 1989; 181: 175-182.
3.Arrigoni ME, Caso V: Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001; 27: 27-49.
4.Nishida N, Sugimoto T, Araki A. Carnitine metabolism in valproate- treated rats: the effect of L-carnitine supplementation. Ped Res 1987; 22: 500-503.
5.Camina MF, Rozas I, Gomez JM. Short-term effects of administra tion of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues. Br J Pharmacol 1991; 103: 179-1183
. 6.Beghi E, Bizzi A, Codegoni. Valproate, carnitine metabolism, and bi ochemical indicators of liver function. Epilepsia 1990; 31: 346-352.
7.Riva R, Albani F, Gobbi G. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993; 34: 184- 187.
8.Laub MC, Brunner IP, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia 1986; 27: 559-562.
9.Eyer F, Felgenhauer N, Gempel K. Acute valproate poisoning: phar- macokinetics, alteration in fatty acid metabolism, and changes du ring therapy. J Clin Psychopharmacol 2005; 25: 376-380.
10.Silva MF, Jakobs C, Duran M. Valproate induces in vitro accumula tion of long-chain fatty acylcarnitines. Mol Genet Metab 2001; 73: 358-361.
11.Matsuda I, Ohtani Y, Ninomiya N. Renal handling of carnitine in children with carnitine deficiency and hyperamonemia associated with valproate therapy. J Pediatr 1986; 109: 131-134.
12.Camina MF, Rozas I, Gago C. Alteration of renal carnitine metabo lism by anticonvulsant treatment. Neurol 1991; 41: 1444-1448.
13.Silva MFB, Selhorst J, Overmans H. Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI- MS/MS. Clin Biochem 2001; 34: 635-638.
14.Chace DH, Hillman SL, Va Hove JLK, Naylor EW. Rapid diagno sis of MCAD deficiency: quantative analysis of octanocarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem . 1997; 43: 2160-2113.
15.Moreno FA, Macey H, Schreiber B. Carnitine levels in valproic acid- treated psychiatric patients: a cross-sectional study. J Clin Psychiatry 2005; 66:555-558.
16.Murakami K, Sugimoto T, Nishida N. Carnitine metabolism and morphometric change of liver mitochondria in valproate-treated rats. Neuropediatrics 1990; 21: 187-190.
17.Sugimoto T, Woo M, Nishida N. Hepatotoxicity in rat following ad ministration of valproic acid. Epilepsia 1987; 28: 142-146.